Replies to post #109364 on Biotech Values

[jq1234]

I predict that VEGF-Trap-Eye will be a commercial bust

What's your definition of commercial bust? You think REGN/Bayer's drug at peak can't get 20% of Lucentis worldwide sales? 20% off current Lucentis sale is $600m/year.

Despite supposed off-label usage of Avastin, Lucentis sales have continued to rise quite rapidly.